Rhythm Pharmaceuticals gains Japan approval for IMCIVREE in hypothalamic obesity

BIOG

Rhythm Pharmaceuticals has received approval from Japan’s Ministry of Health, Labour and Welfare for IMCIVREE, or setmelanotide, to treat acquired hypothalamic obesity.

IMCIVREE is the first treatment approved in the country specifically for acquired hypothalamic obesity.

Rhythm expects to make IMCIVREE available in Japan before the end of 2026, subject to final pricing arrangements. This means the regulatory risk has been reduced, while pricing and commercial execution now become the main factors determining how quickly the Japanese opportunity can begin contributing to the business.

Rhythm estimates that around 5,000 to 8,000 people in Japan are living with acquired hypothalamic obesity.

Acquired hypothalamic obesity can occur following damage to the hypothalamus, including after surgery or treatment for certain tumours. The condition can lead to rapid and difficult-to-control weight gain because the hypothalamus plays a central role in regulating hunger, energy use and body weight.

IMCIVREE is designed to act on the melanocortin-4 receptor pathway, known as the MC4R pathway. Rhythm has built its development strategy around rare forms of obesity where disruption of this pathway contributes to severe hunger and weight gain.

Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value. 

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Cancer research advances bring new treatment options and improve patient outcomes

Advances in cancer research are expanding treatment options, improving early detection and developing more personalised approaches....

Drug development continues to create opportunities for medical innovation

The development of new medicines combines scientific research, clinical trials and regulatory review to bring potential treatments closer to...

The Biotech Growth Trust: Recent Sector Weakness Could Present an Opportunity, Says Kepler Partners

The Biotech Growth Trust could benefit from renewed pharmaceutical acquisitions and biotechnology innovation, according to Kepler Partners research....

Biotech Growth Trust positioned to benefit from sector recovery: Kepler

Kepler research highlights the potential for Biotech Growth Trust (BIOG) to benefit from a recovery in biotech stocks, supported...

Alzheimer’s research advances as new treatments and diagnostic tests emerge

Alzheimer’s research is advancing through new treatments, blood-based diagnostic tests and investigations into amyloid, tau and other disease mechanisms,...

Revolution Medicines advances cancer drug pipeline as European launch plans take shape

Revolution Medicines advances its European launch plans for RASONQUE following a positive EMA recommendation, while expanding its Phase 3...

Search